Literature DB >> 22773722

Levamisole-adulterated cocaine: a case series.

Gerald W Morris1, Bryan C Mason, Rachael Harris Sprunger, Holly Hake Harris, Luke A White, Dale A Patterson.   

Abstract

The percentage of cocaine adulterated with levamisole is steadily increasing in the United States. In susceptible persons, this combination of drugs leads to a clinical syndrome that can include leukopenia and cutaneous manifestations. Many patients also demonstrate positive autoimmune markers. Biopsies of skin lesions often reveal a thrombotic pattern, leukocytoclastic vasculitis, or both. We report 2 cases of this clinical phenomenon, one of which was severe enough to require skin grafting. It is important for clinicians be aware of this emerging public health threat.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22773722     DOI: 10.3122/jabfm.2012.04.110287

Source DB:  PubMed          Journal:  J Am Board Fam Med        ISSN: 1557-2625            Impact factor:   2.657


  4 in total

1.  Correlation between cocaine prices and purity with trends in emergency department visits in a major metropolitan area.

Authors:  He Zhu; Fernando A Wilson; Jim P Stimpson; José A Pagán
Journal:  J Urban Health       Date:  2014-10       Impact factor: 3.671

Review 2.  DARK Classics in Chemical Neuroscience: Aminorex Analogues.

Authors:  Julian Maier; Felix P Mayer; Simon D Brandt; Harald H Sitte
Journal:  ACS Chem Neurosci       Date:  2018-10-05       Impact factor: 5.780

3.  Antineutrophil cytoplasmic antibody mediated glomerulonephritis associated with levamisole-adulterated cocaine.

Authors:  Zita Shiue; Bairbre McNicholas; Fionnuala Cormack; Shreeram Akilesh
Journal:  Clin Nephrol Case Stud       Date:  2014-12-15

4.  Spectrum of acute kidney injury associated with cocaine use: report of three cases.

Authors:  José Célio Costa Lima Filho; Maurício Yukio Ogawa; Tacilla Hanny de Souza Andrade; Sami de Andrade Cordeiro Gadelha; Paula Frassinetti Castelo Branco Camurça Fernandes; Anaiara Lucena Queiroz; Elizabeth De Francesco Daher
Journal:  BMC Nephrol       Date:  2019-03-20       Impact factor: 2.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.